e-learning
resources
Stockholm 2007
Tuesday 18.09.2007
Diagnosis and prognosis in thoracic oncology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Validity of predictive estimate by physicians of the survival of patients with recently diagnosed stages IIIB and IV non-small cells lung cancer (NSCLC)
C. Clement-Duchene, C. Carnin, T. Roederer, F. Guillemin, Y. Martinet (Vandoeuvre-lès-Nancy, France)
Source:
Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Session:
Diagnosis and prognosis in thoracic oncology
Session type:
Electronic Poster Discussion
Number:
3189
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Clement-Duchene, C. Carnin, T. Roederer, F. Guillemin, Y. Martinet (Vandoeuvre-lès-Nancy, France). Validity of predictive estimate by physicians of the survival of patients with recently diagnosed stages IIIB and IV non-small cells lung cancer (NSCLC). Eur Respir J 2007; 30: Suppl. 51, 3189
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Related content which might interest you:
Analysis of prognostic factors in patients with stage IIIB, IV non-small cell lung cancer
Source: Annual Congress 2010 - Staging of lung cancer
Year: 2010
Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019
FEV
1
is not a prognostic marker in operated patients with stage I or II non-small cell lung cancer (NSCLC)
Source: Annual Congress 2011 - Surgery for lung cancer: pre-operative evaluation and results
Year: 2011
Stage IIIB and stage IV non-small cell lung cancers; responses to treatment and survival durations
Source: Eur Respir J 2004; 24: Suppl. 48, 302s
Year: 2004
A new TNM classification is better than ISS at predicting survival in stage III unresectable non-small cell lung cancer (NSCLC). A study by the European lung cancer working party (ELCWP)
Source: Eur Respir J 2003; 22: Suppl. 45, 163s
Year: 2003
Prognostic factors in patients with resected pathologic stage I and II nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 269s
Year: 2002
Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019
Main reasons for a low accrual pattern in clinical trials of patients with advanced stage non-small cell lung cancer (NSCLC)
Source: Annual Congress 2008 - Influence of teaching models on skills and knowledge of medical doctors
Year: 2008
Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019
Radiotherapy for stage III non-small cell lung cancer (NSCLC)
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)?
Source: Eur Respir J 2004; 24: Suppl. 48, 76s
Year: 2004
Stage IIIA-N2 non-small cell lung cancer (NSCLC): comparison of prognostic factors in 257 patients treated with surgery (S) versus induction chemotherapy plus surgery (IC+S)
Source: Eur Respir J 2002; 20: Suppl. 38, 597s
Year: 2002
Independent prognostic und predictive value of blood vessel invasion (BVI) in curatively (R0) resected stage II and IIIA non-small cell lung (NSCLC) cancer patients
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
Age and stage at presentation in lung cancer
Source: Annual Congress 2005 - Management of lung cancer: clinical problems
Year: 2005
Selective adjuvant chemotherapy according to in-vitro chemoresistance test: Long term follow up of patients with resectable non-small cell lung cancer (NSCLC) stage IIIA
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Survival impact of surgery in the treatment of stage IIIB-IVA non-small cell lung cancer
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018
Survival of patients operated for stage I non-small-cell lung cancer
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008
Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Actual challenges in thoracic surgery
Year: 2010
Management of locally advanced nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 260–270
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept